Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Eli Lilly and Company -0.76% Pre

Eli Lilly and Company

LLY

922.50

928.84

-0.76%

+0.69% Pre

- Novo Nordisk NOVOb.CO said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s Tirzepatide in reducing body weight.